Walleye Capital’s Viking Therapeutics VKTX Stock Holding History

Walleye Capital’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$361K	Sell	11,100 -71,900	-87%	-$2.31M	﹤0.01%	2925
2025 Q4	$2.92M	Sell	83,000 -3,200	-4%	-$113K	0.01%	1557
2025 Q3	$2.27M	Buy	86,200 +62,300	+261%	+$1.86M	0.01%	1473
2025 Q2	$633K	Sell	23,900 -19,400	-45%	-$511K	﹤0.01%	2436
2025 Q1	$1.05M	Buy	43,300 +14,900	+52%	+$471K	﹤0.01%	1937
2024 Q4	$1.14M	Sell	28,400 -14,500	-34%	-$827K	﹤0.01%	2272
2024 Q3	$2.72M	Buy	42,900 +34,500	+411%	+$2.02M	0.01%	1671
2024 Q2	$445K	Buy	8,400 +7,800	+1,300%	+$511K	﹤0.01%	3604
2024 Q1	$49.2K	Sell	600 -7,200	-92%	-$320K	﹤0.01%	4683
2023 Q4	$145K	Buy	+7,800	New	+$102K	﹤0.01%	3861
2023 Q3	–	Sell	-4,400	Closed	-$71.3K	–	5358
2023 Q2	$71.3K	Buy	4,400 +1,800	+69%	+$37.7K	﹤0.01%	3537
2023 Q1	$43.3K	Buy	+2,600	New	+$26.9K	﹤0.01%	3239

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Walleye Capital's VKTX Position: Q1 2026 in Review

Walleye Capital reduced its Viking Therapeutics (VKTX) stake by 95% in Q1 2026, selling an estimated $2.63M and leaving 4,573 shares worth $149K. The position accounts for ﹤0.01% of the portfolio, ranked #3499.

Walleye Capital first reported a position in VKTX in Q3 2018 and has held it in 17 quarters since. The position peaked at $3.04M in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Walleye Capital held 4,573 shares of Viking Therapeutics worth $149K as of Q1 2026.
Walleye Capital sold 81,798 Viking Therapeutics shares in Q1 2026, an estimated $2.63M.
Viking Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3499 holding.
Walleye Capital first reported a position in Viking Therapeutics in Q3 2018 and has held it in 17 quarters since.
Walleye Capital's Viking Therapeutics position peaked at $3.04M in Q4 2025.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.